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ABSTRACT		
	
Background	
Organ	preserving	strategies	for	rectal	cancer	patients	that	achieve	a	complete	clinical	response	(cCR)	after	
neoadjuvant	therapy	such	as	watch	and	wait	(W&W)	are	gaining	interest	among	patients	and	clinicians.	In	
absence	of	evidence	from	randomized	controlled	trials,	the	International	Watch	&	Wait	Database	(IWWD)	
was	initiated	in	2014.	We	aimed	to	describe	the	outcome	of	W&W	patients	based	on	pooled	individual	
patient	data.		
	
Methods	
Participating	centres	entered	data	into	an	online	highly	secured	and	encrypted	research	data	server.	Data	
included	 baseline	 characteristics,	 neoadjuvant	 therapy,	 imaging	 protocols,	 local	 regrowth,	 distant	
metastases	 rate	and	survival	 status.	The	present	analysis	 concerns	all	patients	with	a	clinical	 complete	
response	(cCR)	after	neoadjuvant	treatment	who	were	managed	by	W&W.		
	
Findings	
Between	April	2015	and	June	2017,	1009	patients	were	identified	in	the	database	from	47	participating	
institutes	(15	countries).	880	patients	(87%)	with	a	cCR	were	included.	Median	follow-up	time	was	3·4	
years	(IQR	1·8	to	5·5).	Two-year	local	regrowth	rate	was	25·3%	(95%CI	22·3-28·6%),	88·3%	of	all	local	
regrowth	was	diagnosed	in	the	first	two	years,	and	was	located	in	the	bowel	wall	in	96·7%.	Five-year	overall	
survival	was	84·6%	(95%CI	80·8-87·6%),	and	five-year	disease-specific	survival	was	93·8%	(95%CI	90·8-
95·8%).		
	
Interpretation	
This	 is	 the	 largest	 series	 of	 patients	 with	 rectal	 cancer	 treated	 with	 a	W&W	 approach,	 consisting	 of	
approximately	50%	data	from	previous	cohort	series	and	50%	unpublished	data.	Local	regrowth	occurs	
mostly	in	the	first	two	years	and	in	the	bowel	wall,	emphasizing	the	importance	of	endoscopic	surveillance	
to	ensure	the	option	of	deferred	curative	surgery.	Local	unsalvageable	disease	after	W&W	was	rare.	It	is	
our	hypothesis	that	the	majority	of	the	6%	rectal	cancer-specific	death	was	more	related	to	tumour	biology	
rather	than	to	omission	of	surgery.	
	
Funding		
European	 Registration	 of	 Cancer	 Care	 (EURECCA)	 financed	 by	 European	 Society	 of	 Surgical	 oncology	
(ESSO),	Champalimaud	foundation	Lisbon,	“Bas	Mulder	Award”	granted	by	the Alpe	d’Huzes	foundation/	
Dutch	Cancer	Society,	European	Research	Council	Advanced	Grant.	
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INTRODUCTION	
	
Long-term	survival	for	locally	advanced	rectal	cancer	has	improved	considerably	since	the	introduction	of	
total	 mesorectal	 excision	 and	 neoadjuvant	 (chemo-)radiotherapy.1	 However,	 this	 treatment	 remains	
associated	with	perioperative	mortality	of	2%	and	up	to	four	times	higher	in	the	elderly.2,3	In	addition,	it	
can	 lead	 to	 temporary	 or	 permanent	 colostomy,	 and	 serious	 long-term	morbidity	 such	 as	 urinary	 and	
sexual	dysfunction	in	more	than	60%	of	patients.4	Over	the	last	years	focus	has	shifted	towards	a	more	
individualized	approach	with	the	aim	of	improving	long-term	quality	of	life	and	functional	outcomes.	This	
has	led	to	a	growing	interest	in	organ	preserving	strategies	in	a	strictly	selected	population.		
	
Combining	neoadjuvant	chemo-	and	radiotherapy	has	proven	 to	be	effective	 to	downstage	 the	primary	
tumour	and	it	 leads	in	about	20%	of	the	patients	to	complete	disappearance	of	the	tumour	and	tumour	
positive	lymph	nodes,	a	pathological	complete	response	(pCR),	which	is	associated	with	favourable	long-
term	outcomes	compared	to	those	without	complete	response	.5,6		
	
Since	the	first	introduction	of	watch	and	wait	(W&W)	for	rectal	cancer	patients	with	a	clinical	complete	
response	 (cCR)	 after	 neoadjuvant	 chemoradiotherapy	 by	 Habr-Gama,7	 multiple	 cohort	 series	 are	 now	
available	in	which	surgery	has	been	omitted.8-11	It	is	known	that	the	diagnosis	of	a	cCR	based	on	the	results	
of	 conventional	 imaging	modalities	does	not	perfectly	correspond	 to	a	 true	CR,	as	 local	 regrowth	rates	
within	2	years	of	follow	up	range	from	7	to	33%.12,13	Despite	local	tumour	regrowth	rates,	the	results	so	far	
are	 promising	 in	 terms	 of	 survival	 since	 the	 vast	majority	 of	 local	 regrowths	 are	 amenable	 to	 salvage	
resection.	In	a	recent	meta-analysis,	no	overall	survival	benefit	was	suggested	for	surgical	resection	versus	
W&W	in	patients	with	a	cCR.12		
	
Several	factors	may	have	contributed	for	a	limited	adoption	of	such	strategy	so	far	and	its	absence	in	most	
surgical	 oncology	 guidelines.	 Most	 available	 cohort	 series	 are	 small	 and	 have	 heterogeneous	 study	
populations,	and	 therefore	are	not	adequate	 to	define	 the	 individualized	oncological	 risk.	Furthermore,	
international	consensus	on	imaging	strategies	and	timing	to	identify	a	cCR,	or	to	detect	cancer	regrowth	
timely,	is	still	lacking.	Also,	neoadjuvant	treatment	schedules,	choice	of	chemotherapy	and	radiotherapy	
dosage	are	considerably	variable	across	studies,	subsequently	resulting	in	a	wide	range	complete	clinical	
response	rates	(10	to	78%).9,10	Finally,	data	on	long-term	survival	outcomes	such	as	functional	and	quality	
of	life	results	are	still	scarce.	
	
In	this	setting,	more	evidence	supporting	organ-preserving	strategies	is	needed	to	implement	W&W	as	a	
safe	treatment	option	for	selected	cases.	Randomized	controlled	trials	for	this	indication	are	challenging	
for	both	practical	and	ethical	reasons:	Patients	are	likely	to	prefer	avoiding	surgery,	especially	when	they	
are	facing	permanent	colostomy.	The	International	Watch	&	Wait	database	 (IWWD)	was	established	 in	
February	2014.14	This	was	initiated	by	a	collaboration	of	high-profile	clinical	experts,	under	the	umbrella	
of	EURECCA	(European	Registration	of	Cancer	Care)	and	the	Champalimaud	Foundation	Lisbon.	The	aim	
of	 this	database	is	 to	collect	all	 available	data	 in	order	to	expand	knowledge	on	 the	benefits,	 risks	and	
oncological	safety	of	organ	preserving	strategies	in	rectal	cancer.	For	the	present	study,	the	primary	aim	
was	to	describe	the	pooled	information	after	collection	of	patient-data	of	more	than	1000	patients	from	our	
network,	which	consists	of	data	from	previously	published	cohort	series	and	about	50%	of	unpublished	
data	from	smaller	W&W	centres.	Furthermore,	we	aimed	to	explore	the	local	regrowth-rate	and	survival	in	
this	population.		
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METHODS		
	
Study	design		
This	is	an	international	multicentre	registry	study.	In	April	2015,	the	web-based	database	was	opened	for	
patient	 data	 registry.	Data	 entry	 is	 performed	online	 at	 participating	centres	 under	 supervision	 of	 the	
participating	investigator,	and	stored	in	a	highly	secured	NEN7510	certified	and	encrypted	research	data	
server	(ProMISe).15	The	IWWD	database	contains	information	on	patient	and	tumour	characteristics	at	the	
time	 of	 diagnosis,	 the	 reason	 for	 organ-preserving	 treatment,	 type	 of	 neoadjuvant	 therapy,	 results	 of	
imaging	modalities	 at	 diagnosis,	 reassessment	 after	 neoadjuvant	 therapy	 and	 follow-up,	 details	 of	 the	
treatment	for	disease	recurrence,	and	survival	status.	All	assessments	were	done	according	to	local	W&W	
protocol	 of	 the	 participating	 institutions.	 Data	 quality	 checks	were	 performed	 by	 the	 data	 centre.	 All	
participating	centres	retain	full	ownership	of	their	data	and	responsibility	for	accuracy	in	the	information	
provided.		
	
Patient	selection		
All	patients	with	rectal	cancer	in	whom	the	standard	of	care,	TME	surgery,	was	omitted	after	neoadjuvant	
therapy	are	eligible	to	be	included	in	the	IWWD.	For	the	present	analysis,	we	included	patients	with	a	cCR	
only,	as	defined	according	to	each	institution’s	criteria.	This	could	be	patients	who	were	treated	with	strict	
surveillance	only,	as	well	as	patients	without	suspicion	of	residual	tumour	in	whom	a	standard	confirmative	
local	excision	was	performed.	All	other	reasons	for	inclusion	in	the	database,	as	well	as	patients	diagnosed	
with	distant	metastasis	at	baseline	but	a	local	complete	clinical	response	were	excluded	for	this	analysis.	
	
Outcomes		
The	primary	aim	was	 to	describe	 the	available	 information	on	 internationally	applied	W&W	strategies	
within	our	network.	For	baseline	clinical	tumour	stage,	data	of	all	performed	radiologic	imaging	modalities	
at	baseline	were	combined.	If	MRI	was	performed,	this	was	considered	the	leading	imaging	modality.	The	
incidence	of	local	tumour	regrowth	and	distant	metastasis	during	follow-up	was	assessed.	Since	the	2014	
Champalimaud	consensus	meeting,	it	is	agreed	that	local	tumour	regrowth	after	an	initial	cCR	should	be	
distinguished	from	local	recurrence	after	TME	surgery,	which	is	known	for	its	poor	prognosis,	whereas	
local	regrowth	(after	a	cCR)	is	usually	readily	salvageable.16	Therefore,	this	is	indicated	as	local	regrowth-
rate	 in	 the	 present	 study.	 Furthermore,	 overall	 survival	 (OS)	 and	 disease-specific	 survival	 (DSS)	were	
assessed.	 For	 analysis	 of	 DSS,	 deaths	 due	 to	 the	 primary	 malignancy	 (local	 disease	 and/or	 distant	
metastasis	of	rectal	cancer)	or	related	to	treatment	were	considered	an	event.		
	
Statistical	analysis		
Statistical	 analysis	 was	 performed	 using	 IBM	 SPSS	 Statistics	 version	 23.0	 and	 Stata/SE	 version	 12.0.	
Descriptive	features	were	calculated	for	the	whole	registry,	no	comparisons	were	made.	Median	follow-up	
was	calculated	according	to	the	reverse	Kaplan-Meier	method.	The	time	to	diagnosis	of	local	regrowth	was	
calculated	from	the	date	of	decision	for	W&W.	For	survival	analysis	Kaplan-Meier	survival	methods	were	
used.	Date	of	diagnosis	was	considered	the	baseline	time	point	for	survival	analysis	and	the	actuarial	rate	
of	distant	metastasis.	If	the	date	of	diagnosis	was	unknown,	this	was	estimated	using	the	dates	of	endoscopy	
and	imaging	at	baseline.		
	
Ethical	approval		
This	is	an	observational	registry	study.	Data	is	entered	into	the	online	data	server	in	a	coded	format.	Ethical	
approval	was	handled	according	to	local	authorities	per	participating	institute.		
	
Role	of	the	funding	source		
The	 funders	 had	no	 role	 in	 the	 study	design,	 data	analysis	 or	writing	 the	 report.	 The	members	 of	 the	
executive	board	of	 the	 IWWD	consortium	shared	 the	responsibility	 for	 the	 final	decision	 to	submit	 the	
report	for	publication.		
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RESULTS		
	
Patient	characteristics		
On	June	30th,	2017,	1009	patients	were	included	in	the	database	from	47	participating	institutes	and	15	
countries	(appendix	B).	Of	these,	880	patients	had	a	cCR	as	defined	by	the	criteria	of	participating	institutes,	
and	were	included	for	the	present	analysis.	Other	reasons	for	inclusion	in	the	database	but	exclusion	for	
this	analysis	were	clinical	near	complete	response,	or	patient	related	factors	such	as	refusal	of	surgery	by	
patient	or	inoperability	due	to	comorbidity	(figure	1).	Patient	and	tumour	characteristics	at	baseline	are	
listed	in	table	1.	There	was	great	variability	between	baseline	characteristics	from	included	centres.	When	
looking	at	the	three	largest	centres	of	our	network,	some	differences	were	noted	(appendix	C).		
Diagnostic	procedures		
Imaging	modalities	 used	 at	 baseline	 and	 reassessment	 for	 local	 staging	 are	 listed	 in	 table	 2.	 Baseline	
imaging	protocols	were	varying.	Almost	all	patients	underwent	endoscopy	at	baseline	(96·4%),	and	in	the	
three-quarters	of	patients	MRI	imaging	was	performed	(77·0%).		
	
For	 identification	 of	a	 cCR	after	 neoadjuvant	 therapy,	endoscopy	was	 performed	 in	 88·5%	of	 cases.	 In	
44·9%	of	all	patients	that	underwent	endoscopy	for	reassesment	after	neoadjuvant	therapy,	biopsies	were	
taken.	Restaging	MRI	was	performed	in	70·5%	of	all	patients.	Less	frequently	performed	were	CT	pelvis	
and	endorectal	ultrasound	(29·7%	and	7·6%	respectively).	In	most	patients	(70·6%)	two	or	more	imaging	
modalities	were	combined	for	local	restaging.	Both	endoscopy	and	MRI	were	done	in	64·0%	of	all	patients.	
A	combination	of	DRE,	endoscopy	and	MRI	was	performed	in	45·2%	of	patients.	In	44	patients	local	excision	
was	performed	in	the	initial	treatment	window	without	clinical	evidence	of	local	regrowth	–	of	these,	88·6%	
had	no	residual	adenocarcinoma.	
		
Neoadjuvant	therapy		
Chemoradiotherapy	 was	 most	 commonly	 used	 (804/880	 patients,	 91·4%),	 with	 schedules	 of	 45	 Gy	
(24·6%),	50-50·4	Gy	(50·4%),	54	Gy	(14·5%)	or	60	Gy	 (5·7%).	In	the	majority	of	patients	capecitabine	
(61·5%)	or	5-FU	(29·2%)	was	used.	The	compliance	of	chemoradiotherapy	was	high:	98·8%	of	all	patients	
completed	all	radiotherapy,	and	95·1%	of	patients	completed	the	chemotherapy	component.	
The	different	combinations	of	neoadjuvant	therapy	are	displayed	in	table	3.	In	seven	patients,	the	details	
of	neoadjuvant	therapy	were	unknown.		
	
Local	regrowth	
Local	regrowth	occurred	in	213	out	of	880	patients,	with	a	2-year	actuarial	rate	of	25·3%	(95%CI	22·3-
28·6%).	In	63·8%	(n=136)	local	regrowth	was	diagnosed	in	the	first	year	after	the	decision	for	a	W&W	
regimen,	and	in	88·3%	(n=158)	within	two	years	(figure	2).	Local	regrowths	were	located	in	the	bowel	wall	
in	 96·7%.	 In	 11	 patients	 local	 regrowth	 was	 located	 in	 the	 regional	 lymph	 nodes,	 in	 four	 of	 whom	
simultaneously	with	tumour	regrowth	in	the	bowel	wall.	Only	seven	patients	were	diagnosed	with	tumour	
regrowth	in	the	regional	lymph	nodes	only	(3·3%).		
	
For	148	out	of	213	patients	with	local	regrowth,	details	of	surgical	treatment	for	regrowth	were	available.		
Of	these,	46	patients	were	treated	with	local	excision	(31·1%),	of	which	13	underwent	additional	surgical	
resection	 subsequently.	 In	 total	 115	patients	 underwent	TME	 resection	 for	 local	 regrowth	 (77·7%),	 of	
which	99·1%	with	curative	intention.	In	87·8%	of	all	surgical	resections	for	local	regrowth,	the	resection	
margins	were	 tumour	negative	 (R0	resection),	 in	6·1%	tumour	margins	were	positive	 (R+),	and	 in	 the	
remaining	cases	the	margin	involvment	was	unknown	(6·1%).	
	
Distant	metastasis		
Distant	metastasis	were	diagnosed	in	71	patients	during	follow-up,	with	a	3-year	actuarial	rate	of	7·6%	
(95%CI	5·8-10.0).	Only	9·9%	(n=7)	of	all	distant	metastasis	were	diagnosed	in	the	first	year	after	diagnosis,	
47·9%	(n=34)	were	diagnosed	within	2	years,	and	67·6%	(n=48)	within	3	years.		
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Distant	metastasis	were	most	 frequently	 located	in	 lungs	 (62·0%),	 followed	by	 liver	 (40·8%).	Thirteen	
patients	(18·3%)	were	diagnosed	with	lung	and	liver	metastasis	simultaneously.	Other	locations	of	distant	
metastasis	were	distant	lymph	nodes	(11·3%)	and	peritoneum	(5·6%).		
In	 patients	with	 local	 regrowth,	 the	 incidence	 of	 distant	metastasis	was	 17·8%	 (38/213),	 whereas	 in	
patients	with	a	sustained	complete	response	this	was	4·9%	(33/634).	Of	the	patients	with	both	distant	
metastasis	and	 local	 regrowth,	 the	 distant	metastases	were	 diagnosed	prior	 to	 the	 local	 regrowth	 in	 2	
patients	(5·3%),	simultaneously	in	12	patients	(within	3	months,	31·6%),	and	more	than	3	months	after	
the	local	regrowth	in	19	patients	(50·0%).	For	five	patients	(13·2%)	the	time	between	local	regrowth	and	
distant	metastasis	was	unknown.		
	
Survival	
Five-year	DSS	was	93·8%	(95%CI	90·8	-	95·8)	and	5-year	OS	was	84·6%	(95%CI	80·8	-	87·6)	(figure	3).	For	
patients	with	a	sustained	cCR,	the	5-year	DSS	was	97·3%	(95%CI	94·5-98·7)	and	5-year	OS	was	87·9%	
(95%CI	 83·8-91·0).	 For	 patients	 that	were	 diagnosed	with	 local	 regrowth,	 the	 5-year	 DSS	was	 84·0%	
(95%CI	75·0-89·9)	and	5-year	OS	75·4%	(95%CI	66·2-82·4).	
In	33	patients	 (3·75%)	 the	cause	of	death	was	related	 to	 rectal	 cancer.	Ten	patients	died	of	metastatic	
disease	in	the	presence	of	a	sustained	local	cCR.	Fourteen	patients	who	died	of	rectal	cancer	were	diagnosed	
with	both	distant	metastasis	and	local	regrowth,	and	five	patients	only	had	local	residual	disease	at	the	time	
of	death.	Of	these	five	patients,	two	had	undergone	surgical	resection	for	regrowth	with	curative	intention,	
one	had	refused	surgery,	and	in	two	patients	the	details	were	unknown.	In	the	four	remaining	patients,	the	
sites	of	rectal	cancer	at	death	were	unknown.		
	
	
DISCUSSION	
This	 is	 the	 largest	 series	of	pooled	 individual	data	of	 rectal	 cancer	patients	with	a	W&W	strategy	after	
neoadjuvant	therapy.	The	main	aim	of	this	study	was	to	provide	an	insight	in	the	strategies	and	real	world	
oncological	outcome	of	W&W	series	worldwide.	The	registry	has	collected	data	of	more	than	1000	patients,	
approximately	50%	from	published	cohort	studies,	and	50%	of	unpublished	data.7,8,10,11,17-19		
In	the	registry,	25·3%	of	patients	in	a	W&W	approach	developed	a	local	regrowth	in	the	first	two	years	of	
follow-up.	This	 local	regrowth	rate	 is	considerably	higher	than	the	pooled	2-year	local	regrowth	rate	of	
15·7%	reported	in	the	meta-analyis	of	Dossa	et	al.	This	is	probably	explained	by	the	strict	inclusion	criteria	
in	the	studies	of	the	meta-analysis,	whereas	the	registry	is	more	based	on	an	‘	all-comers’	strategy	without	
narrow	 selection	 criteria.	 Most	 likely	 this	 better	 reflects	 the	 outcome	 of	 a	W&W	 strategy	 on	 a	 more	
population-based	level.	The	regrowths	were	nearly	always	located	in	the	bowel	wall	(97%),	highlighting	
the	importance	of	endoscopic	assessments	in	the	follow-up	protocols	for	W&W	strategies.	
	
The	survival	outcome	in	this	W&W	population	is	excellent:	a	5-year	OS	of	84·6%	and	a	5-year	DSS	of	93·8%.	
Despite	the	heterogeneity	in	the	registry,	these	5-year	outcome	figures	are	remarkable	good	compared	to	
survival	rates	of	rectal	cancer	patients	who	undergo	surgery.20	The	main	concern	about	implementation	of	
W&W	strategies	remains	whether	survival	and	the	chance	of	curative	treatment	are	compromised	by	not	
performing	immediate	surgery	in	patients	with	a	clinical	complete	response,	but	rather	to	delay	surgery	
and	restrict	it	to	only	those	patients	who	experience	a	regrowth.	It	is	clear	that	patients	with	a	sustained	
complete	response	are	better	off	with	a	W&W	policy,	as	immediate	TME	surgery	could	not	have	improved	
their	100%	local	control	rate,	and	could	only	have	contributed	operative	mortality	and	short	and	long	term	
morbidity.	The	oncological	prognosis	should	be	broadly	similar	to	pCR	patients	after	TME	surgery.	The	
87·9%	5-year	OS	in	patients	with	a	sustained	clinical	complete	response	in	the	present	study	is	comparable	
to	the	5-year	OS	of	87·6%	in	pCR	patients	in	the	pooled	analysis	of	Maas	et	al.6	Patients	with	a	regrowth	are	
at	least	theoretically	at	risk	to	develop	uncurable	local	disease,	and	to	develop	metastases	arising	from	the	
regrowth.	
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In	 this	 study,	 five	out	of	880	patients	died	of	 local	 tumour	recurrence	 (0·6%).	In	 two	of	 these	patients	
salvage	treatment	was	technically	not	possible,	one	patients	declined	treatment,	and	in	two	patients	the	
reason	was	not	documented.	If	we	presume	the	worst	case	scenario,	that	all	four	patients	in	which	the	sites	
of	rectal	cancer	were	unknown	also	died	of	local	uncontrollable	disease,	the	risk	of	locally	unsalvagable	
disease	would	be	between	0·2%	to	1·3%.	This	is	within	the	same	range	of	the	0.2%	reported	in	the	recent	
meta-analysis	 of	Dossa	 and	collegues.12	Due	 to	 the	 inclusion	 of	 unpublished	 series	and	patients	 in	 our	
registry,	this	figure	is	most	likely	a	reliable	reflection	of	the	true	population	risk.	It	can	be	used	in	a	trade-
off	discussion	with	a	patient	with	a	clinical	complete	response	to	decide	between	a	W&W	policy	and	TME	
surgery.	The	benefits	of	a	radical	resection	should	be	balanced	against	the	operative	risk,	short	and	long	
term	morbidity	and	risk	for	definitive	colostomy.		
	
It	is	more	difficult	to	estimate	the	excess	risk	of	metastatic	disease	in	patients	with	a	regrowth,	if	there	is	
any.	Patients	with	a	regrowth	most	 likely	would	have	shown	residual	tumour	and	would	not	have	been	
labeled	pCR	 if	 they	would	have	had	TME	surgery	after	 the	chemoradiation.	 It	 is	well	documented	 that	
incomplete	 responders	 have	 an	 inherently	 higher	 risk	 for	 metastases	 and	 a	 lower	 OS	 than	 complete	
responders,	suggesting	a	more	unfavorable	biological	profile.	In	the	pooled	analysis	of	Maas	et	al.	22·7%	of	
non-pCR	patients	developed	metastasis	and	5-year	OS	was	76·5%.6	In	our	data,	distant	metastasis	were	
diagnosed	in	17·8%	of	patients	that	were	diagnosed	with	local	regrowth,	and	their	5-year	OS	was	75·4%.	
Although	the	two	populations	are	somewhat	different,	the	figures	are	in	the	same	range.	It	is	our	hypothesis	
that	the	majority	of	the	6%	deaths	due	to	rectal	cancer	in	the	present	series	are	due	to	metastatic	disease	
that	was	already	present	at	the	time	of	diagnosis	and	treatment,	and	therefore	related	to	the	biology	of	the	
tumor	rather	then	to	the	omission	of	TME	surgery.	
	
This	study	has	several	limitations.	First	of	all,	this	is	a	database-based	registry	study.	As	expected,	we	found	
considerable	variances	between	participating	centers	in	baseline	characteristics,	neoadjuvant	therapy	and	
imaging	strategies.	Although	all	participants	have	performed	data	entry	with	the	same	instructions	and	
agreements,	and	multiple	quality	checks	were	performed	to	detect	entry	errors,	it	is	possible	that	items	are	
interpreted	and	filled	in	differently.	We	did	not	have	access	to	the	original	patient	reports,	causing	missing	
data	on	some	details	of	imaging	and	treatment	strategies.	For	example,	details	on	the	treatment	for	local	
regrowth	was	avaliable	in	only	69%	of	cases.	This	might	be	caused	by	the	fact	that	W&W	patients	are	often	
referred	from	W&W	expert	centers	to	their	primary	hospital	 for	salvage	therapy.	However,	the	survival	
status	was	available.	Because	part	of	the	data	was	prospectively	collected	at	the	participating	institutes,	but	
entered	at	a	later	date	in	the	IWWD,	it	is	possible	that	not	all	patients	that	initially	were	selected	for	W&W	
strategies	are	included	in	the	database,	potentially	leading	to	selection	bias.		
	
Despite	these	limitations,	we	feel	that	the	results	of	this	study	are	valuable	and	increase	the	knowledge	on	
the	risks	and	benefits	of	W&W	for	individual	patients.	The	data	collected	so	far	show	the	importance	of	
frequent	endoscopic	 surveillance	 in	W&W	patients	 in	 the	 first	 two	years	of	 follow-up,	 the	 location	and	
incidence	of	distant	metastasis	and	the	small	risk	of	incurable	disease.	However,	many	uncertainties	and	
clinical	 challenges	 remain.	 Importantly,	 long-term	 quality	 of	 life	 outcomes,	 and	 effects	 of	
(chemo)radiotherapy	on	bowel	function	in	W&W	patients	are	still	unknown.	As	the	percentage	of	cancer	
survivors	 is	 growing	 rapidly	 due	 to	 population	 screening	 and	 improved	 therapeutic	 strategies,	 the	
importance	of	quality	of	life	outcomes	and	patient	preferences	grows	concomittantly.		
	
It	 is	our	aim	to	expand	the	expert	network	on	organ	preservation	 in	rectal	cancer	within	the	IWWD	to	
provide	evidence	for	the	development	of	uniform	neoadjuvant	treatment,	imaging	and	follow-up	protocols,	
specifically	including	quality	of	life	and	functional	outcomes.	An	international	consensus	meeting	on	W&W	
strategies	is	scheduled	for	the	end	of	2018.	Moreover,	by	prospective	collection	of	population-based	data,	
we	aim	 to	 improve	 the	estimation	 of	 individualized	 risks,	 and	 to	 aid	 shared-decision	making	 between	
doctors	 and	 patients.	 The	 IWWD	 consortium	 welcomes	 all	 interested	 clinicians	 that	 perform	 organ	
preserving	stategies	in	rectal	cancer	patients	to	join	our	network.		
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Table	1:	Patient	characteristics	at	baseline	
Data	are	displayed	as	n(%),	unless	indicated	otherwise.		
BMI=body	mass	index	
	
		 	 N=880	(%)	
Age	 Mean	(SD)	 63.6	(11·7)	
BMI	 Mean	(SD)	 26.7	(4·9)	
Sex	 Male	
Female	
603	(68·5)	
277	(31·5)	
Comorbidity		
	
	
yes	
no	
unknown	
252	(28·6)	
337	(38·3)	
273	(33·1)	
Country	 Argentina	
Belgium	
Brazil	
Germany	
Denmark	
France	
Great	Britain	
Ireland	
the	Netherlands	
Poland	
Portugal	
Russia	
Sweden	
Turkey	
46	(5·2)	
27	(3·1)	
201	(22·8)	
25	(2·8)	
40	(4·5)	
42	(4.8)	
150	(17·0)	
35	(4·0)	
252	(28·6)	
15	(1·7)	
21	(2·4)	
5	(0·6)	
15	(1·7)	
6	(0·7)	
Year	of	
decision	for	
W&W	
Before	2010	
2010-2014	
2015	-	present	
177	(20·2)	
450	(51·1)	
253	(28·8)	
clinical	T	
stage	baseline	
cT1	
cT2	
cT3	
cT4	
unknown	
14(1·6)	
226	(25·7)	
451	(51·3)	
30	(3·4)	
159	(18·1)	
clinical	N	
stage	baseline	
cN0	
cN1	
cN2	
unknown	
309	(35·1)	
271	(30·8)	
167	(19·0)	
133	(15·1)	
Last	study	
status	
In	follow-up	
Follow-up	completed	
Lost	to	follow-up	
Deceased	
660	(75·0)	
57	(6·5)	
64	(7·3)	
99	(11·3)	
 13 
 
Table	2:	Diagnostic	procedures	at	baseline	and	at	reassessment	after	induction	therapy.		
Data	are	displayed	as	n(%).		
	
	 Baseline:	n	(%)	 Reassessment:	n	(%)	
Endoscopy		 848	(96·4)	 779	(88·5)	
MRI	pelvis	 678	(77·0)	 620	(70·5)	
CT	pelvis	 378	(43·0)	 261	(29·7)	
Endorectal	ultrasound	 146	(16·6)	 67	(7·6)	
PET	scan		 116	(13·2)	 39	(4·4)	
CEA	 540	(61·4)	 196	(22·3)	
Local	excision	
ypT0	
ypT+	
-	
45	(5·0)	
40	
5	
	
	
Table	3:	Different	types	and	combinations	of	induction	therapy		
Data	are	displayed	as	frequencies	(n).	
CRT=	Chemo-radiotherapy,	BRT=	Brachy	radiotherapy,	EBT=	External-beam	radiotherapy,	CT=	Chemotherapy.		
	
Single	therapy	 n	
	 Chemo-radiotherapy	(CRT)		 738	
	 Brachy	radiotherapy	(BRT)	 5	
	 External	beam	radiotherapy	(EBT)	 35	
	 Chemotherapy(CT)		 3	
	 Total	 781	
	 	 	
Different	combinations	 	
	 CRT	+	BRT		 57	
	 CRT+	CT	 7	
	 BRT+	EBT	 19	
	 EBT+	CT	 7	
	 CRT+	BRT+	EBT	 2	
	 Total		 92	
Missing	 	 7		
Total	 	 880	
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